References
Blom, D. J., R. Dent, R. C. Castro, and P. P. Toth. 2016. PCSK9 inhibition in the management of hyperlipidemia: Focus on evolocumab. Vascular Health and Risk Management 12:185–197.
Bunnage, M. E. 2011. Getting pharmaceutical R&D back on target. Nature Chemical Biology 7(6):335–339.
Clark, K., K. F. MacKenzie, K. Petkevicius, Y. Kristariyanto, J. Zhang, H. G. Choi, M. Peggie, L. Plater, P. G. Pedrioli, E. McIver, N. S. Gray, J. S. Arthur, and P. Cohen. 2012. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proceedings of the National Academy of Sciences of the United States of America 109(42):16986–16991.
Collins, F. S., and H. Varmus. 2015. A new initiative on precision medicine. New England Journal of Medicine 372(9):793–795.
Dewey, F. E., V. Gusarova, C. O’Dushlaine, O. Gottesman, J. Trejos, C. Hunt, C. V. Van Hout, L. Habegger, D. Buckler, K. M. Lai, J. B. Leader, M. F. Murray, M. D. Ritchie, H. L. Kirchner, D. H. Ledbetter, J. Penn, A. Lopez, I. B. Borecki, J. D. Overton, J. G. Reid, D. J. Carey, A. J. Murphy, G. D. Yancopoulos, A. Baras, J. Gromada, and A. R. Shuldiner. 2016. Inactivating variants in ANGPTL4 and risk of coronary artery disease. New England Journal of Medicine 374(12):1123–1133.
DiMasi, J. A., H. G. Grabowski, and R. W. Hansen. 2016. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics 47:20–33.
Filippakopoulos, P., J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp, and J. E. Bradner. 2010. Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073.
Flannick, J., et al. 2014. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nature Genetics 46(4):357–363.
Helgadottir, A., S. Gretarsdottir, G. Thorleifsson, E. Hjartarson, A. Sigurdsson, A. Magnusdottir, A. Jonasdottir, H. Kristjansson, P. Sulem, A. Oddsson, G. Sveinbjornsson, V. Steinthorsdottir, T. Rafnar, G. Masson, I. Jonsdottir, I. Olafsson, G. I. Eyjolfsson, O. Sigurdardottir, M. S. Daneshpour, D. Khalili, F. Azizi, D. W. Swinkels, L. Kiemeney, A. A. Quyyumi, A. I. Levey, R. S. Patel, S. S. Hayek, I. J. Gudmundsdottir, G. Thorgeirsson, U. Thorsteinsdottir, D. F. Gudbjartsson, H. Holm, and K. Stefánsson. 2016. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics 48:634–639.
Hodes, R. J., and N. Buckholtz. 2016. Accelerating Medicines Partnership: Alzheimer’s Disease (AMP-AD) knowledge portal aids Alzheimer’s drug discovery through open data sharing. Expert Opinion on Therapeutic Targets 20(4):389–391.
HRSA (Health Resources and Services Administration). 2014. HRSA Health Center Program, Bureau of Primary Health Care. http://bphc.hrsa.gov/about/healthcenterfactsheet.pdf (accessed June 20, 2016).
Hu, Y., A. Shmygelska, D. Tran, N. Eriksson, J. Y. Tung, and D. A. Hinds. 2016. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nature Communications 7:10448.
Jonsson, T., J. K. Atwal, S. Steinberg, J. Snaedal, P. V. Jonsson, S. Bjornsson, H. Stefansson, P. Sulem, D. Gudbjartsson, J. Maloney, K. Hoyte, A. Gustafson, Y. Liu, Y. Lu, T. Bhangale, R. R. Graham, J. Huttenlocher, G. Bjornsdottir, O. A. Andreassen, E. G. Jonsson, A. Palotie, T. W. Behrens, O. T. Magnusson, A. Kong, U. Thorsteinsdottir, R. J. Watts, and K. Stefánsson. 2012. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488(7409):96–99.
Jonsson, T., H. Stefansson, S. Steinberg, I. Jonsdottir, P. V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A. I. Levey, J. J. Lah, D. Rujescu, H. Hampel, I. Giegling, O. A. Andreassen, K. Engedal, I. Ulstein, S. Djurovic, C. Ibrahim-Verbaas, A. Hofman, M. A. Ikram, C. M. van Duijn, U. Thorsteinsdottir, A. Kong, and K. Stefánsson. 2013. Variant of TREM2 associated with the risk of Alzheimer’s disease. New England Journal of Medicine 368(2):107–116.
Kalow, W., and B. K. Tang. 1993. The use of caffeine for enzyme assays: A critical appraisal. Clinical Pharmacology & Therapeutics 53(5):503–514.
Karczewski, K. J., R. Daneshjou, and R. B. Altman. 2012. Chapter 7: Pharmacogenomics. PLOS Computational Biology 8(12):e1002817.
Liu, T., and R. B. Altman. 2011. Using multiple microenvironments to find similar ligand-binding sites: Application to kinase inhibitor binding. PLOS Computational Biology 7(12):e1002326.
Liu, J. Z., et al. 2013. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics 45(6):670–675.
McClellan, J., and M. C. King. 2010. Genetic Heterogeneity in Human Disease. Cell 141(2):210–217.
The Michael J. Fox Foundation. 2015. Parkinson’s Biomarker Initiative expands genetic study. https://www.michaeljfox.org/foundation/publicationdetail.html?id=578&category=7 (accessed June 6, 2016).
Nelson, M. R., H. Tipney, J. L. Painter, J. Shen, P. Nicoletti, Y. Shen, A. Floratos, P. C. Sham, M. J. Li, J. Wang, L. R. Cardon, J. C. Whittaker, and P. Sanseau. 2015. The support of human genetic evidence for approved drug indications. Nature Genetics 47(8):856–860.
NIH (National Institutes of Health). 2014. Physician-scientist workforce (PSW) report 2014. Rockville, MD: National Institutes of Health. https://report.nih.gov/workforce/psw/index.aspx (accessed July 3, 2016).
Nioi, P., et al. 2016. Variant ASGR1 associated with a reduced risk of coronary artery disease. New England Journal of Medicine 374(22):2131–2141.
NLM (National Library of Medicine). 2016. Pulmonary arterial hypertension. https://ghr.nlm.nih.gov/condition/pulmonary-arterial-hypertension#resources (accessed May 25, 2016).
Ono, M., T. Shimizugawa, M. Shimamura, K. Yoshida, C. Noji-Sakikawa, Y. Ando, R. Koishi, and H. Furukawa. 2003. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. Journal of Biological Chemistry 278(43):41804–41809.
Pasche, B., and D. Absher. 2011. Whole-genome sequencing: A step closer to personalized medicine. JAMA 305(15):1596–1597.
Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427.
Scott, R. A., et al. 2016. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine 8(341):341ra376.
Smith, C. 2003. Drug target validation: Hitting the target. Nature 422(6929):341, 343, 345.
Stacey, S. N., H. Helgason, S. A. Gudjonsson, G. Thorleifsson, F. Zink, A. Sigurdsson, B. Kehr, J. Gudmundsson, P. Sulem, B. Sigurgeirsson, K. R. Benediktsdottir, K. Thorisdottir, R. Ragnarsson, V. Fuentelsaz, C. Corredera, Y. Gilaberte, M. Grasa, D. Planelles, O. Sanmartin, P. Rudnai, E. Gurzau, K. Koppova, B. A. Nexo, A. Tjonneland, K. Overvad, J. G. Jonasson, L. Tryggvadottir, H. Johannsdottir, A. M. Kristinsdottir, H. Stefansson, G. Masson, O. T. Magnusson, B. V. Halldorsson, A. Kong, T. Rafnar, U. Thorsteinsdottir, U. Vogel, R. Kumar, E. Nagore, J. I. Mayordomo, D. F. Gudbjartsson, J. H. Olafsson, and K. Stefánsson. 2015. New basal cell carcinoma susceptibility loci. Nature Communications 6:6825.
Steinberg, S., H. Stefansson, T. Jonsson, H. Johannsdottir, A. Ingason, H. Helgason, P. Sulem, O. T. Magnusson, S. A. Gudjonsson, U. Unnsteinsdottir, A. Kong, S. Helisalmi, H. Soininen, J. J. Lah, DemGene, D. Aarsland, T. Fladby, I. D. Ulstein, S. Djurovic, S. B. Sando, L. R. White, G. P. Knudsen, L. T. Westlye, G. Selbaek, I. Giegling, H. Hampel, M. Hiltunen, A. I. Levey, O. A. Andreassen, D. Rujescu, P. V. Jonsson, S. Bjornsson, J. Snaedal, and K. Stefánsson. 2015. Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nature Genetics 47(5):445–447.
Steinthorsdottir, V., G. Thorleifsson, P. Sulem, H. Helgason, N. Grarup, A. Sigurdsson, H. T. Helgadottir, H. Johannsdottir, O. T. Magnusson, S. A. Gudjonsson, J. M. Justesen, M. N. Harder, M. E. Jorgensen, C. Christensen, I. Brandslund, A. Sandbaek, T. Lauritzen, H. Vestergaard, A. Linneberg, T. Jorgensen, T. Hansen, M. S. Daneshpour, M. S. Fallah, A. B. Hreidarsson, G. Sigurdsson, F. Azizi, R. Benediktsson, G. Masson, A. Helgason, A. Kong, D. F. Gudbjartsson, O. Pedersen, U. Thorsteinsdottir, and K. Stefánsson. 2014. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nature Genetics 46(3):294–298.
Styrkarsdottir, U., G. Thorleifsson, S. A. Gudjonsson, A. Sigurdsson, J. R. Center, S. H. Lee, T. V. Nguyen, T. C. Kwok, J. S. Lee, S. C. Ho, J. Woo, P. C. Leung, B. J. Kim, T. Rafnar, L. A. Kiemeney, T. Ingvarsson, J. M. Koh, N. L. Tang, J. A. Eisman, C. Christiansen, G. Sigurdsson, U. Thorsteinsdottir, and K. Stefánsson. 2016. Sequence variants in the PTCH1 gene associate with spine bone mineral density and osteoporotic fractures. Nature Communications 7:10129.
Sukonina, V., A. Lookene, T. Olivecrona, and G. Olivecrona. 2006. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proceedings of the National Academy of Sciences of the United States of America 103(46):17450–17455.
Tatonetti, N. P., J. C. Denny, S. N. Murphy, G. H. Fernald, G. Krishnan, V. Castro, P. Yue, P. S. Tsao, I. Kohane, D. M. Roden, and R. B. Altman. 2011. Detecting drug interactions from adverse-event reports: Interaction between paroxetine and pravastatin increases blood glucose levels. Clinical Pharmacology and Therapeutics 90(1):133–142.
Tufts Center for the Study of Drug Development. 2014. How the Tufts Center for the Study of Drug Development pegged the cost of a new drug at $2.6 billion. http://csdd.tufts.edu/files/uploads/cost_study_backgrounder.pdf (accessed July 3, 2016).
Tung, J. Y., C. B. Do, D. A. Hinds, A. K. Kiefer, J. M. Macpherson, A. B. Chowdry, U. Francke, B. T. Naughton, J. L. Mountain, A. Wojcicki, and N. Eriksson. 2011. Efficient replication of over 180 genetic associations with self-reported medical data. PLoS ONE 6(8):e23473.
Wang, G., M. L. McCain, L. Yang, A. He, F. S. Pasqualini, A. Agarwal, H. Yuan, D. Jiang, D. Zhang, L. Zangi, J. Geva, A. E. Roberts, Q. Ma, J. Ding, J. Chen, D. Z. Wang, K. Li, J. Wang, R. J. Wanders, W. Kulik, F. M. Vaz, M. A. Laflamme, C. E. Murry, K. R. Chien, R. I. Kelley, G. M. Church, K. K. Parker, and W. T. Pu. 2014. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nature Medicine 20(6):616–623.
Whirl-Carrillo, M., E. M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C. F. Thorn, R. B. Altman, and T. E. Klein. 2012. Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacololgy & Therapeutics 92(4):414–417.
This page intentionally left blank.
